Home - GeneHelix.com

Home

Newsflash

Genehelix brings a large database of Bioinformatics companies and institutes with complete profiles and current job openings . Search here for your company profile...

Main Menu

Bioinformatics Course

About Us

No account yet? Create one

Deals in this month

Novartis Bristol-Myers Squibb $660 million acquisition of US and Canadian OTC division Novartis gains rights to a broad range of OTC drugs, including Excedrin and Comtrex.
Last Updated ( Friday, 22 July 2005 )
Read more...

‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug–drug inter

Amin Rostami-Hodjegan and Geoff Tucker Recently, metabolic drug–drug interactions (M-DDI) have raised some high-profile problems in drug development resulting in restricted use, withdrawal or non-approval by regulatory agencies. The use of in vitro technologies to evaluate the potential for M-DDI has become routine in the drug development process. Nevertheless, in the absence of an integrated approach, their interpretation and value remains the subject of debate, and the vital distinction between a useful “simulation” and a precise “prediction” is not often appreciated. Various in silico softwares are now available for the simulation of M-DDI. However, a concerted effort by the industry is necessary to evaluate their use. The FDA has recently emphasised the importance of such collaboration to improve the crucial path to development of new drugs. In silico simulation of M-DDI has the potential to add significant value to this process.
Last Updated ( Saturday, 16 July 2005 )
Read more...

Automation and robotics in ADME screening

Kenneth C. Saunders^,

Automation Team, Department of Pharmacokinetics Dynamics and Metabolism, Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, UK CT13 9NJ

The use of automated sample processing, analytics and screening technology for profiling absorption, distribution, metabolism and excretion (ADME) and physicochemical properties, early in the drug discovery process, is becoming more widespread. The use and application of these technologies is both diverse and innovative. High-throughput screening (HTS) technologies have been utilised enabling the profiling of an increased number of compounds emerging from the drug discovery process. Although the drivers for using these technologies are common, different approaches can be taken.

Last Updated ( Sunday, 05 June 2005 )